Status:
UNKNOWN
Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
The myeloid-derived suppressor cells (MDSCs) can further trigger cytotoxic T cell apoptosis, and may shift the macrophages toward M2 subtype, inhibit the Th1 cell, and initiate other immune suppressiv...
Detailed Description
Lung cancer is the leading cause of mortality and morbidity in the world. In Taiwan, lung cancer is the second cause of cancer death in men and the first in women. Although the five-year survival rate...
Eligibility Criteria
Inclusion
- Patients with pathological diagnosis of primary non-small-cell lung cancer Stage IIIB, IV
- Age ≧ 18 years
- Written, informed consent
- ECOG: 0-1
Exclusion
- Subjects with inflammatory, infectious or immune disorder, such as TB, AIDS, active pneumonia, DM, SLE, rheumatoid disease.
- Subjects with systemic organ disease, such as CHF, ESRD, hepatitis, liver cirrhosis.
- Subjects with malignancy other than NSCLC.
- Subjects receiving anti-inflammatory or immunosuppressor medications, such as steroid (oral, except for chemotherapy premedication, or inhaled), NSAIDs.
- Patients with no willing to sign the informed consent
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2014
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01802021
Start Date
May 1 2009
End Date
February 1 2014
Last Update
March 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for traditional chinese medicine, Chang Gung Memorial Hospital
Gueishan Township, Taoyuan County, Taiwan, 33378